New drug combo aims to slow muscle decline in rare disease

NCT ID NCT06479863

Recruiting now Disease control Sponsor: Austin Neuromuscular Center Source: ClinicalTrials.gov ↗

First seen Jan 20, 2026 · Last updated May 16, 2026 · Updated 14 times

Summary

This early-phase study tests whether a combination of two drugs, pozelimab and cemdisiran, can help people with sporadic inclusion body myositis (sIBM), a rare muscle disease that causes progressive weakness. Ten adults aged 45 to 75 with sIBM will receive the treatment and be monitored for changes in physical function and muscle strength. The goal is to see if the therapy can slow or improve muscle decline.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Austin Neuromuscular Center
RECRUITING

Austin, Texas, 78759, United States
Austin Neuromuscular Center
RECRUITING

Austin, Texas, 78759, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC INFLAMMATORY MYOPATHIES SPORADIC INCLUSION BODY MYOSITIS (SIBM)